Purpose: To evaluate health care utilization, treatment patterns and costs among patients with mycosis fungoides-cutaneous T-cell lymphoma (MF-CTCL). Methods: This retrospective cohort study queried the HealthCore Integrated Research Database to identify patients ≥18 years with ≥2 diagnoses of MF-CTCL (ICD-9-CM code 202.1x, 202.2x) between 07 January 2006 and 07 January 2013. Index date was defined as first MF-CTCL diagnosis. Patients were continuously enrolled ≥6 months before and ≥12 months after index date. Severe MF-CTCL was identified via systemic therapy use postindex. Generalized linear model (GLM) was used to estimate the relationship between MF-CTCL severity and healthcare costs controlling for selected factors. Results: A total of 1981 MF-CTCL patients were evaluated: 493 (24.9%) severe and 1488 (75.1%) with mild to moderate disease. GLM analysis indicated severe MF-CTCL patients incurred higher all-cause healthcare total costs compared to patients with mild-to-moderate MF-CTCL (coefficient estimate: 4.19, p < .0001). About 51% of patients did not receive any MF-CTCL-specific treatment within 60 days after MF-CTCL diagnosis. Conclusions: MF-CTCL severity was associated with greater healthcare resource utilization and costs. These findings suggest that about half of MF-CTCL patients do not receive MF-CTCL-specific treatment within 60 days following initial diagnosis. Future studies are needed to understand reasons for delayed treatment initiation.
Ocrelizumab (OCR), natalizumab (NTZ), and alemtuzumab (ATZ) are infusible drugs to treat patients with multiple sclerosis (MS). We did a study to understand the costs of these infusible MS drugs in real-world settings by analyzing a patients’ pharmacy and medical claims database. A total of 1,058 patients were included. We found that the annual total costs increased substantially after patients started to use these infusible MS drugs. Specifically, the average first- and second-year total costs for patients were $125,597 and $109,618 for OCR, $117,033 and $106,626 for NTZ, and $179,809 and $108,636 for ATZ, respectively. We also found that the cost of the drug itself is the main driver for the overall healthcare spending, accounting for >78% of the total costs. Additionally, we found that the cost varies depending on where patients receive these infusible MS drugs, and generally speaking, infusions received from hospital outpatient settings would be more expensive than received from home settings. In summary, this study showed that the real-world costs of these infusible MS drugs are very high. Shifting patients away from more costly hospital outpatient departments or using MS drugs that do not require infusion resources (e.g., oral/self-injectable) may help reduce the overall healthcare spending on MS. Graphical Abstract
Objectives: We aimed to describe the demographics, clinical characteristics and care patterns of patients with systemic autoimmune rheumatic diseases (SARD) prior to their interstitial lung disease (ILD) diagnosis. Methods: We conducted a retrospective cohort study using claims data from Healthcare Integrated Research Database (2006–2023). Adults diagnosed with SARD-ILD were identified, with the earliest ILD diagnosis date designated as the index date. A minimum of 36 months of continuous enrolment before the index date was required. All measures were analysed descriptively. For a subset of patients with respiratory symptoms before ILD diagnosis, the association between type of specialist encounter and time from symptom onset to SARD-ILD diagnosis was assessed using a Cox proportional hazards model. Results: The study included 2526 patients with SARD-ILD. Mean age was 62.6 years and 75.4% were female. Before ILD diagnosis, 61.8% of patients had at least one all-cause hospitalization. Diagnostic tests including chest CT, high-resolution CT, and pulmonary function tests (PFT) were used in 80.1%, 59.0% and 60.3% of patients, respectively. Among the subgroup, patients who saw a pulmonologist within 90 days of initial respiratory symptom onset were 18% more likely to be diagnosed with ILD compared with those who did not (hazard ratio: 1.18, 95% CI: 1.03, 1.35; P = 0.017). Conclusion: The study highlights the complex diagnostic journey of patients with SARD-ILD. Findings suggest a multidisciplinary approach involving pulmonologists and rheumatologists could enable timely ILD diagnosis and should be considered for more effective diagnosis and management of SARD-ILD.
22 October 2022 in Current Medical Research and Opinion
To evaluate the trend in cytogenetic/molecular testing rate in chronic lymphocytic leukemia (CLL) and assess the clinical and economic burden of first-line (1 L) treatment with chemoimmunotherapy (...